HUMIRA IS THE FIRST
FDA-APPROVED TREATMENT FOR HS
The Role of HUMIRA in HS
Clinically Meaningful Improvement
HiSCR Requires the Following Relative to Baseline1,5
HiSCR requires counting abscesses, inflammatory nodules, and draining tunnels before and after an intervention.5
†HiSCR=Hidradenitis Suppurativa Clinical Response.
Well-Studied Safety Profile of HUMIRA
HUMIRA has clinical trial experience across 11 immune-mediated diseases. HUMIRA has been studied in adults with HS in 3 controlled studies and an open-label extension study, and the safety profile for adult patients with HS treated with weekly dosing was consistent with the known safety profile of HUMIRA.1,10
treated in clinical studies1
of clinical trial experience beginning with rheumatoid arthritis in 199711
Up to 3 years of safety data in HS,
including open-label extension6
including 5 pediatric indications and the first FDA-approved treatment for moderate to severe HS1,4
Experience in Dermatology
of clinical experience in dermatology14
have been prescribed HUMIRA for HS since its FDA approval in 201515§
§Information derived from PatientSource data provided by Symphony Health and IQVIA (NSP) for HS (Sep 2015) through Mar 2020
Watch “Navigating the Unknown”
Reflections on HS from HS-treating dermatologists, a pediatrician, and actual patients.
Members of the HS care team, including HS-treating dermatologists and a pediatrician, discuss the importance of timely identification and appropriate treatment of HS. Actual HS patients discuss the impact HUMIRA has had on their journey with HS.